Fate Therapeutics Inc.
| NASDAQ: FATE | Healthcare / Biotechnology / USA |
| 77.99 | -1.02 | -1.29% | Vol 778.33K | 1Y Perf 185.38% |
| Apr 9th, 2021 16:00 DELAYED |
| BID | 77.00 | ASK | 78.74 | ||
| Open | 78.32 | Previous Close | 79.01 | ||
| Pre-Market | - | After-Market | 77.99 | ||
| - - | - -% |
| Target Price | 110.07 | Analyst Rating | Strong Buy 1.25 | |
| Potential % | 41.13 | Finscreener Ranking | ★★★★+ 56.10 | |
| Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★+ 53.80 | |
| Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★ 60.50 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
| Market Cap | 7.31B | Earnings Rating | Sell | |
| Price Range Ratio 52W % | 54.82 | Earnings Date | 10th May 2021 |
Today's Price Range 76.1780.80 | 52W Range 25.60121.16 | 5 Year PE Ratio Range -11.60-3.20 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -4.79% | ||
| 1 Month | -13.20% | ||
| 3 Months | -32.95% | ||
| 6 Months | 62.45% | ||
| 1 Year | 185.38% | ||
| 3 Years | 675.25% | ||
| 5 Years | 3 544.39% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -53.26 | |||
ROE last 12 Months | -53.28 | |||
ROA (5Y Avg) | -18.23 | |||
ROA last 12 Months | -36.44 | |||
ROC (5Y Avg) | -47.50 | |||
ROC last 12 Months | -36.97 | |||
Return on invested Capital Q | -10.78 | |||
Return on invested Capital Y | -46.66 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 10.40 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -39.40 | ||||
| 20.11 | ||||
| 265.63 | ||||
| - | ||||
| -467.90 | ||||
| -0.48 | ||||
| 19.98 | ||||
| 4.10 | ||||
| 7.30B | ||||
| Forward PE | -36.89 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.70 | ||||
| 5.80 | ||||
| 0.20 | ||||
| 0.25 | ||||
| -275.20 | ||||
| Leverage Ratio | 1.50 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -807.20 | ||||
| -791.70 | ||||
| -936.40 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 28.92M | ||||
| 0.31 | ||||
| 99.76 | ||||
| 46.77 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.38 | -0.38 | 0.00 |
| Q03 2020 | -0.29 | -0.36 | -24.14 |
| Q02 2020 | -0.20 | -0.35 | -75.00 |
| Q01 2020 | -0.38 | -0.44 | -15.79 |
| Q04 2019 | -0.39 | -0.37 | 5.13 |
| Q03 2019 | -0.38 | -0.40 | -5.26 |
| Q02 2019 | -0.32 | -0.36 | -12.50 |
| Q01 2019 | -0.23 | -0.30 | -30.43 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.43 | -4.88 | Negative |
| 6/2021 QR | -0.44 | -4.76 | Negative |
| 12/2021 FY | -1.84 | -4.55 | Negative |
| 12/2022 FY | -2.22 | -12.69 | Negative |
| Next Report Date | 10th May 2021 |
| Estimated EPS Next Report | -0.43 |
| Estimates Count | 9 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 778.33K |
| Shares Outstanding | 93.78M |
| Trades Count | 13.20K |
| Dollar Volume | 116.79M |
| Avg. Volume | 1.07M |
| Avg. Weekly Volume | 644.95K |
| Avg. Monthly Volume | 1.05M |
| Avg. Quarterly Volume | 996.14K |
Fate Therapeutics Inc. (NASDAQ: FATE) stock closed at 77.99 per share at the end of the most recent trading day (a -1.29% change compared to the prior day closing price) with a volume of 778.65K shares and market capitalization of 7.31B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 279 people. Fate Therapeutics Inc. CEO is J. Scott Wolchko.
The one-year performance of Fate Therapeutics Inc. stock is 185.38%, while year-to-date (YTD) performance is -14.23%. FATE stock has a five-year performance of 3544.39%. Its 52-week range is between 25.6 and 121.16, which gives FATE stock a 52-week price range ratio of 54.82%
Fate Therapeutics Inc. currently has a PE ratio of -39.40, a price-to-book (PB) ratio of 20.11, a price-to-sale (PS) ratio of 265.63, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -36.44%, a ROC of -36.97% and a ROE of -53.28%. The company’s profit margin is -%, its EBITDA margin is -791.70%, and its revenue ttm is $28.92 Million , which makes it $0.31 revenue per share.
Of the last four earnings reports from Fate Therapeutics Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.43 for the next earnings report. Fate Therapeutics Inc.’s next earnings report date is 10th May 2021.
The consensus rating of Wall Street analysts for Fate Therapeutics Inc. is Strong Buy (1.25), with a target price of $110.07, which is +41.13% compared to the current price. The earnings rating for Fate Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Fate Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Fate Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 12.98, ATR14 : 9.21, CCI20 : -85.67, Chaikin Money Flow : -0.07, MACD : -3.97, Money Flow Index : 41.00, ROC : -12.32, RSI : 44.79, STOCH (14,3) : 34.38, STOCH RSI : 0.77, UO : 51.23, Williams %R : -65.62), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Fate Therapeutics Inc. in the last 12-months were: Bahram Valamehr (Option Excercise at a value of $68 778), Bahram Valamehr (Sold 83 884 shares of value $6 729 621 ), Cindy Tahl (Option Excercise at a value of $471 750), Cindy Tahl (Sold 179 483 shares of value $11 573 326 ), Daniel D. Shoemaker (Sold 84 482 shares of value $5 336 625 ), J. Scott Wolchko (Option Excercise at a value of $760 308), J. Scott Wolchko (Sold 229 407 shares of value $21 102 772 )
Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
CEO: J. Scott Wolchko
Telephone: +1 858 875-1800
Address: 3535 General Atomics Court, San Diego 92121, CA, US
Number of employees: 279
